Signaturefd LLC Lowers Stake in CureVac N.V. $CVAC

Signaturefd LLC lessened its holdings in CureVac N.V. (NASDAQ:CVAC) by 30.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,825 shares of the company’s stock after selling 9,606 shares during the period. Signaturefd LLC’s holdings in CureVac were worth $119,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Two Sigma Investments LP purchased a new stake in shares of CureVac in the fourth quarter valued at approximately $391,000. Two Sigma Advisers LP purchased a new position in shares of CureVac during the 4th quarter valued at approximately $48,000. Nuveen LLC acquired a new stake in CureVac in the 1st quarter valued at $232,000. Greenleaf Trust purchased a new stake in CureVac in the 1st quarter worth $31,000. Finally, GSA Capital Partners LLP acquired a new position in CureVac during the first quarter worth $853,000. Hedge funds and other institutional investors own 17.26% of the company’s stock.

Analyst Ratings Changes

CVAC has been the topic of several research analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of CureVac in a research report on Saturday, September 27th. Jefferies Financial Group reiterated a “hold” rating and issued a $5.00 price objective (down from $7.00) on shares of CureVac in a report on Friday, June 13th. Citizens Jmp lowered CureVac from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 12th. UBS Group downgraded CureVac from a “strong-buy” rating to a “neutral” rating and decreased their target price for the company from $12.00 to $5.50 in a research report on Thursday, June 26th. Finally, Citigroup lowered CureVac to a “market perform” rating in a research note on Thursday, June 12th. One analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $6.83.

CureVac Trading Up 1.1%

Shares of CureVac stock opened at $5.45 on Friday. The company has a current ratio of 6.17, a quick ratio of 6.16 and a debt-to-equity ratio of 0.05. The company has a fifty day simple moving average of $5.40 and a 200-day simple moving average of $4.59. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of 5.68 and a beta of 2.51. CureVac N.V. has a 12-month low of $2.37 and a 12-month high of $5.72.

CureVac (NASDAQ:CVAC) last released its quarterly earnings data on Thursday, August 21st. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.15). The company had revenue of $1.41 million during the quarter, compared to analyst estimates of $4.27 million. CureVac had a net margin of 38.21% and a return on equity of 29.57%. On average, equities analysts forecast that CureVac N.V. will post 0.72 EPS for the current fiscal year.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.